Profusa Inc Dossier - Source-backed chat

Profusa Inc

PFSANASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.87Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.1M

Shares Outstanding 605.7K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Profusa, Inc. (PFSA) is a highly speculative, commercial-stage digital health company facing severe financial distress, extreme dilution risk, and imminent delisting threats. While its proprietary tissue-integrated biosensor technology (the Lumee Oxygen Platform) has demonstrated clinical efficacy and is moving toward European commercialization, the company's balance sheet is highly unstable. With only $0.4 million in cash against $29.1 million in total liabilities as of March 31, 2026, and a massive working capital deficit of $28.4 million, there is substantial doubt about its ability to continue as a going concern. Furthermore, the company's survival is heavily dependent on highly dilutive equity lines of credit and convertible debt facilities, which will continue to exert downward pressure on the stock price.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0230%

The bear case assumes Profusa fails to regain compliance with Nasdaq's listing requirements and is delisted to the OTC markets, severely limiting its access to capital. Delays in obtaining the CE Mark from GMED or failure to close the PanOmics acquisition due to shareholder rejection would halt its commercial roadmap. With a cash runway of less than one quarter and no alternative non-dilutive funding sources, the company would be forced into bankruptcy or a fire-sale liquidation.

Base CaseCentral scenario

$0.2555%

In the base case, Profusa narrowly avoids Nasdaq delisting by executing a highly dilutive reverse stock split (authorized at the June 23, 2026 annual meeting) to artificially boost its share price. The company completes the acquisition of the PanOmics platform by issuing $30 million in convertible preferred stock, leading to massive dilution for existing common shareholders. Commercial revenues from the European launch of the Lumee Oxygen system begin to trickle in during late 2026, but high operational cash burn and debt service obligations force the company to continuously draw down on its Ascent ELOC facility, keeping the stock price depressed.

Bull CaseUpside scenario

$1.5015%

The bull case relies on rapid regulatory approval and commercial execution. If Profusa successfully obtains the CE Mark for its Lumee Oxygen Platform in mid-2026, begins shipping to European distributors to meet or exceed its raised 2026 revenue guidance of $1.5M–$3.0M, and successfully integrates the newly acquired PanOmics molecular diagnostics platform, the company could establish a high-growth, multi-omics precision medicine business. Securing FDA clearance for the Lumee Oxygen system in early 2027 would open up the massive U.S. peripheral artery disease (PAD) and critical limb ischemia (CLI) markets, driving long-term commercial viability.

Scenarios reflect our research view at the research date.

Key Investment Merits

First-in-class tissue-integrated hydrogel biosensor technology capable of continuous, long-term biochemical monitoring without triggering a foreign body response.
Successful clinical trial results for the Lumee Oxygen system in PAD patients, meeting primary endpoints in an FDA-advised study.
Strategic expansion into the high-growth molecular diagnostics market via the planned acquisition of the PanOmics platform.

Key Investment Risks

Severe liquidity constraints with only $0.4 million in cash and a $28.4 million working capital deficit as of Q1 2026, raising substantial going concern doubt.
Extreme dilution risk from outstanding convertible notes, warrants, and the $100 million Ascent equity line of credit, which represents the vast majority of potential outstanding shares.
Imminent Nasdaq delisting risk if the company fails to meet bid price and stockholders' equity requirements by the July 2026 deadlines.

Thesis Invalidation Triggers

Failure to execute the reverse stock split or regain Nasdaq compliance, resulting in immediate delisting.
Rejection of the CE Mark application for the Lumee Oxygen Platform by the European Notified Body GMED.
Inability to access further tranches of the Ascent ELOC or other financing facilities, leading to insolvency.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.